After 24 weeks of treatment, patients may show weight changes and drug-induced obesity, which may also affect patients’ blood glucose, IBIL and SOD because these features are related to metabolism and oxidative stress. This evidence concerns the gene SOD1 and obesity due to melanocortin 4 receptor deficiency.